Post hoc analysis of the AVERT trial in 514 ambulatory cancer patients: higher baseline GDF-15 was associated with VTE (SHR 1.36), NT-proBNP (SHR 1.44) and CRP (SHR 1.38) with clinically relevant bleeding, and rising hs-TnT at 1 month with VTE (SHR 1.89).
Secondary analysisn = 514
Roy et al. Venous thromboembolism and bleeding in cancer patients: role of inflammatory and cardiac biomarkers